Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

(2010) Paul W. Manley et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

(2010) Faye M. Johnson et al.   CANCER

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’

(2010) Gianantonio Rosti et al.   LEUKEMIA & LYMPHOMA

Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy

(2010) Massimo Breccia et al.   LEUKEMIA RESEARCH

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

(2009) G. Rosti et al.   BLOOD

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

(2009) Hagop Kantarjian et al.   CANCER

Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

(2008) M. Hazarika et al.   CLINICAL CANCER RESEARCH